Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study

Circulation

Volumn 121, Issue 13, 2010, Pages 1465-1473

  Sliwa, Karen ^a,b   Blauwet, Lori ^c   Tibazarwa, Kemi ^a,b,d   Libhaber, Elena ^b   Smedema, Jan Peter ^e   Becker, Anthony ^b   McMurray, John ^f   Yamac, Hatice ^g   Labidi, Saida ^g   Struhman, Ingrid ^h   Hilfiker Kleiner, Denise ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e Netcare   (South Africa)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h GIGA R   (Belgium)

Author keywords

Cardiomyopathy; Heart failure; Hormones; Parturition; Pregnancy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BROMOCRIPTINE; C REACTIVE PROTEIN; CARVEDILOL; CATHEPSIN D; CREATININE; ENALAPRIL; FUROSEMIDE; HEMOGLOBIN; PROLACTIN; SPIRONOLACTONE;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PERIPARTUM CARDIOMYOPATHY; PILOT STUDY; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SURVIVAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; BLOOD PRESSURE; BROMOCRIPTINE; CARDIOMYOPATHIES; CATHEPSIN D; FEMALE; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; INFANT, NEWBORN; MIDDLE AGED; PARTURITION; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PROLACTIN; THROMBOEMBOLISM; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 77950902743     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.901496     Document Type: Article

References (30)

1. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006; 368:687-693. (Pubitemid 44223695)
2. Sliwa K, Tibazarwa K, Hilfiker-Kleiner D. Management of peripartum cardiomyopathy. Curr Heart Fail Rep. 2008;5:238-244.
3. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111: 2050-2055. (Pubitemid 40577899)
4. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80:1602-1606.
5. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441-446. (Pubitemid 43209169)
6. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY. Incidence, mortality, and racial differences in peripartum cardiomy-opathy. Am J Cardiol. 2007;100:302-304. (Pubitemid 47041992)
7. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35:701-705. (Pubitemid 30167027)
8. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4: 305-309. (Pubitemid 35190355)
9. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum car-diomyopathy. Cell. 2007;128:589-600.
10. Forster O, Hilfiker-Kleiner D, Ansari AA, Sundstrom JB, Libhaber E, Tshani W, Becker A, Yip A, Klein G, Sliwa K. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10: 861-868.
11. Hilfiker-Kleiner D, Meyer GP, Schieffer E, Goldmann B, Podewski E, Struman I, Fischer P, Drexler H. Recovery from postpartum cardiomy-opathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol. 2007;50:2354-2355.
12. Jahns BG, Stein W, Hilfiker-Kleiner D, Pieske B, Emons G. Peripartum cardiomyopathy: a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol. 2008;199:e5-e6.
13. Iffy L, Lindenthal J, McArdle JJ, Ganesh V. Severe cerebral accidents postpartum in patients taking bromocriptine for milk suppression. Isr J Med Sci. 1996;32:309-312.
14. Hopp L, Weisse AB, Iffy L. Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. Can J Cardiol. 1996; 12:415-418.
15. Loewe C, Dragovic LJ. Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine. Am J Forensic Med Pathol. 1998;19: 258-260.
16. Dutt S, Wong F, Spurway JH. Fatal myocardial infarction associated with bromocriptine for postpartum lactation suppression. Aust N Z J Obstet Gynaecol. 1998;38:116-117.
17. Fett JD. Caution in the use of bromocriptine in peripartum cardiomyop-athy. J Am Coll Cardiol. 2008;51:2083.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echo-cardiographic measurements. Circulation. 1978;58:1072-1083.
19. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777-802.
20. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167-184.
21. World Health Organization. Girls' percentiles. Available at: http://www.who. int/childgrowth/standards/chts-girls-p.pdf. Accessed March 17, 2009.
22. World Health Organization. Boys' percentiles. Available at: http://www. who.int/childgrowth/standards/chts-boys-p.pdf. Accessed March 17, 2009.
23. Habedank D, Kuhnle Y, Elgeti T, Dudenhausen JW, Haverkamp W, Dietz R. Recovery from peripartum cardiomyopathy after treatment with bro-mocriptine. Eur J Heart Fail. 2008;10:1149-1151.
24. Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med. 2008;18: 173-179.
25. Francis GS, Parks R, Cohn JN. The effects of bromocriptine in patients with congestive heart failure. Am Heart J. 1983;106(pt 1):100-106.
26. Goldberg LI. The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1989;14(suppl 5):S19-S27.
27. Wexler BC, McMurtry JP. Hormonal and metabolic changes during acute myocardial infarction in normotensive vs hypertensive rats. Br J Ex Pathol. 1983;64:124-136.
28. Nair VD, Sealfon SC. Agonist-specific transactivation of phosphoinosi-tide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem. 2003;278:47053-47061.
29. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247:1589-1591.
30. James AH, Brancazio LR, Ortel TL. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol. 2005;3:187-197.